论文信息 - LBA52 EMPOWER-Lung 1: Phase III first-line (1L) cemiplimab monotherapy vs platinum-doublet chemotherapy (chemo) in advanced non-small cell lung cancer (NSCLC) with programmed cell death-ligand 1 (PD-L1) ≥50% - 字舞流文

LBA52 EMPOWER-Lung 1: Phase III first-line (1L) cemiplimab monotherapy vs platinum-doublet chemotherapy (chemo) in advanced non-small cell lung cancer (NSCLC) with programmed cell death-ligand 1 (PD-L1) ≥50%

N. Rizvi | I. Lowy | I. Bondarenko | M. Gumus | V. Sriuranpong | P. Clingan | G. Gullo | H. Turk | A. Sezer | I. Çiçin | O. Gladkov | S. Kılıçkap | M. Ozguroglu | P. Rietschel | D. Bentsion | Siyu Li | S. Lee | M. Gogishvili